Boston‑based startup Life Biosciences has secured FDA clearance to begin human trials of its gene‑reprogramming therapy, code‑named ER‑100. The single‑dose viral injection targets glaucoma by resetting ocular cells to a healthier state. The approach draws on Nobel laureate Shinya Yamanaka’s stem‑cell factors and aims for partial cellular reprogramming.

The trial follows public enthusiasm from figures like Elon Musk, who called aging a “solvable” problem at the World Economic Forum in Davos, and David Sinclair, whose anti‑aging ventures have raised over $1 billion. Investors such as biotech funder Karl Pfleger see ER‑100 as a potential foothold in vision‑restoration, not a universal rejuvenation pill.

If early results show safety, the biotech sector could see a surge of capital toward epigenetic therapies, prompting rivals like OpenAI to tout AI‑driven acceleration of longevity research. Regulators will scrutinize cancer‑risk signals observed in animal studies, while clinicians await data to gauge whether ER‑100 can move beyond glaucoma into broader age‑related indications.